title: Topical ivermectin improves allergic skin inflammation.
abstract: BACKGROUND
  Ivermectin (IVM) is widely used in both human and veterinary medicine to treat parasitic infections. Recent reports have suggested that IVM could also have anti-inflammatory properties.
  
  
  METHODS
  Here, we investigated the activity of IVM in a murine model of atopic dermatitis (AD) induced by repeated exposure to the allergen Dermatophagoides farinae, and in standard cellular immunological assays.
  
  
  RESULTS
  Our results show that topical IVM improved allergic skin inflammation by reducing the priming and activation of allergen-specific T cells, as well as the production of inflammatory cytokines. While IVM had no major impact on the functions of dendritic cells in vivo and in vitro, IVM impaired T-cell activation, proliferation, and cytokine production following polyclonal and antigen-specific stimulation.
  
  
  CONCLUSIONS
  Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell-mediated skin inflammatory diseases.
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Ventre
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: A
authors.initials: A
authors.lastname: Rozières
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: V
authors.initials: V
authors.lastname: Lenief
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: F
authors.initials: F
authors.lastname: Albert
authors.affiliation: Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France.
authors.forename: P
authors.initials: P
authors.lastname: Rossio
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: L
authors.initials: L
authors.lastname: Laoubi
authors.affiliation: Université de Lille, INSERM, CHU de Lille, European Genomic Institute of Diabetes, Institut Pasteur de Lille, U1011-récepteurs nucléaires maladies cardiovasculaires et diabète, Lille, France.
authors.forename: D
authors.initials: D
authors.lastname: Dombrowicz
authors.affiliation: Université de Lille, INSERM, CHU de Lille, European Genomic Institute of Diabetes, Institut Pasteur de Lille, U1011-récepteurs nucléaires maladies cardiovasculaires et diabète, Lille, France.
authors.forename: B
authors.initials: B
authors.lastname: Staels
authors.affiliation: Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France.
authors.forename: L
authors.initials: L
authors.lastname: Ulmann
authors.affiliation: Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France.
authors.forename: V
authors.initials: V
authors.lastname: Julia
authors.affiliation: Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France.
authors.forename: E
authors.initials: E
authors.lastname: Vial
authors.affiliation: Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France.
authors.forename: A
authors.initials: A
authors.lastname: Jomard
authors.affiliation: Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France.
authors.forename: F
authors.initials: F
authors.lastname: Hacini-Rachinel
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: J-F
authors.initials: JF
authors.lastname: Nicolas
authors.affiliation: CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.
authors.forename: M
authors.identifier: http://orcid.org/0000-0002-0181-8862
authors.initials: M
authors.lastname: Vocanson
mesh_terms: D000287:Administration, Topical; D000485:Allergens / Q000276:immunology*; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000276:immunology; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D004195:Disease Models, Animal; D058501:Enzyme-Linked Immunospot Assay; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000378:metabolism; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D007559:Ivermectin / Q000008:administration & dosage*; D008213:Lymphocyte Activation / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D058848:Receptors, Purinergic P2X4 / Q000378:metabolism; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
chemical_list: D000485:Allergens; D039741:Antigens, Dermatophagoides; D016207:Cytokines; D051860:Fragile X Messenger Ribonucleoprotein 1; D018836:Inflammation Mediators; D007559:Ivermectin; D058848:Receptors, Purinergic P2X4
keywords: T-cell immunity; atopic dermatitis; ivermectin; skin inflammatory diseases; topical treatment